Feedback
Settings

Settings

Goto Application

6,146 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(USVMJSALORZVDV-SDBHATRESA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 615
1.WO/2025/250823DNA-ENCODED MULTIVALENT ANTIBODIES TARGETING CARBONIC ANHYDRASE 9 AND METHODS OF USE IN CANCER THERAPEUTICS
WO - 04.12.2025
Int.Class C07K 16/40
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
40against enzymes
 Appl.No PCT/US2025/031479 Applicant THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY Inventor O'CONNELL, Ryan
Disclosed herein are methods of treating or preventing renal cell carcinoma comprising administering compositions comprising a recombinant nucleic acid sequence encoding a therapeutic antibody targeting CA9, a fragment thereof, a variant thereof, or a combination thereof.
2.WO/2025/250826PERSISTENT T-CELL ENGAGERS TARGETING FSHR AND METHODS OF USE IN CANCER THERAPEUTICS
WO - 04.12.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2025/031483 Applicant THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY Inventor BORDOLOI, Devivasha
Disclosed herein are compositions comprising persistent bispecific anti-FSHR T cell engagers and a persistent multivalent anti-FSHR T cell engagers, fragments thereof, variants thereof, combinations thereof, and recombinant nucleic acid sequences encoding the same, fragments thereof, variants thereof, combinations thereof, and methods of use thereof.
3.WO/2025/250977CANCER THERAPY USING IL-2 PRODRUG
WO - 04.12.2025
Int.Class A61K 38/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins
 Appl.No PCT/US2025/031709 Applicant WEREWOLF THERAPEUTICS, INC. Inventor MORRIS, Kristin, R.
This disclosure relates to methods and compositions for treating cancer using an inducible IL-2 prodrug, wherein the subject in need thereof has a solid tumor that comprises activated intratumoral effector T cells prior to administration of the IL-2 prodrug.
4.WO/2025/242026CANCER VACCINES AND USES THEREOF
WO - 27.11.2025
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
 Appl.No PCT/CN2025/095665 Applicant EVEREST MEDICINES (CHINA) CO., LTD. Inventor XIE, Liang
Provided herein are nucleic acids, pharmaceutical compositions and vaccines that express two or more cancer antigens. Also provided herein are methods for treating a cancer.
5.20250361315HUMANIZED ANTI-CD84 RECOMBINANT PROTEIN COMPOSITIONS
US - 27.11.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No 19204241 Applicant CITY OF HOPE Inventor John C. WILLIAMS

Provided herein are, inter alia, recombinant proteins and humanized antibodies (e.g., bispecific antibodies, chimeric antigen receptors and humanized antibodies), which bind Cluster of Differentiation 84 (CD84) with high efficiency and specificity. The compositions provided herein include novel light and heavy chain domain CDRs and framework regions and are, inter alia, useful for treating cancer and other CD84-related diseases.

6.20250361203PROCESSES OF MAKING 3-FLUORO-5-(((1S,2AR)-1,3,3,4,4 PENTAFLUORO-2A-HYDROXY-2,2A,3,4-TETRAHYDRO-1H-CYCLOPENTA[CD]INDEN-7-YL)OXY)BENZONITRILE AND POLYMORPHS THEREOF
US - 27.11.2025
Int.Class C07C 255/54
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
255Carboxylic acid nitriles
49having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
54containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
 Appl.No 19293755 Applicant NiKang Therapeutics, Inc. Inventor Charles M. COOK

The present disclosure provides certain processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro- 1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile (Compound 1) and certain polymorphs thereof. Also provided are pharmaceutical compositions comprising a crystalline polymorph form of Compound 1 and processes for preparing such polymorph forms.

7.20250353854FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN
US - 20.11.2025
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
 Appl.No 18871252 Applicant Biomea Fusion, Inc. Inventor James T. PALMER

Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific covalent inhibitors of a menin or menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds described herein. Methods of using the menin or menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin or menin-MLL interaction.

8.20250352655THERAPEUTIC ANNEXIN-DRUG CONJUGATES AND METHODS OF USE
US - 20.11.2025
Int.Class A61K 47/64
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
 Appl.No 19282461 Applicant The Board of Regents of the University of Oklahoma Inventor Roger G. Harrison

Therapeutic protein-drug conjugates comprising annexins conjugated to drug payloads for targeting stressed human cells (e.g., cancer cells), bacterial cells, fungal cells, or parasitic cells which express phosphatidylserine. The protein-drug conjugates generally contain multiple drug molecules per annexin molecule. The annexin binds to the surface of cells, but is also endocytosed efficiently, thereby delivering the drug to the cytoplasm of the target cell.

9.20250352490P-SELECTIN TARGETED NANOPARTICLES AND USES THEREOF
US - 20.11.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No 19287868 Applicant Ramot at Tel-Aviv University Ltd. Inventor Ronit SATCHI-FAINARO

Particles made of a polymeric matrix having associated therewith a therapeutically active agent usable in treating a medical condition associated with an overexpression of P-selectin in a subject in need thereof and featuring a P-selectin selective targeting moiety represented by Formula I as defined and described in the specification and claims, compositions comprises these particles and uses thereof, are provided.

10.WO/2025/240781MODIFIED ANTIBODIES AND IMMUNOGLOBULIN FORMATS
WO - 20.11.2025
Int.Class C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
 Appl.No PCT/US2025/029625 Applicant WEREWOLF THERAPEUTICS, INC. Inventor CAFARELLI, Tiziana
Provided herein are modified antibodies or antibody binding fragments thereof that have inhibited binding activity for their cognate antigens. The antibodies or antibody binding fragments comprise an antigen binding domain and two or more blocking elements that are operably linked through a cleavable linker to the antigen binding domain.
# -